netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.02.01  Expand sub section  Antiproliferative immunosuppressants
Cytotoxic Drug Azathioprine
(Immunosuppression / Post-transplant)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

In line with Shared Care Protocol.

APCO March 2016.

 
Link  UKMI Q&A: Can mothers breastfeed while taking azathioprine?
   
Mycophenolate Mofetil
View adult BNF View SPC online View childrens BNF
Formulary

Amber Traffic Light  For adults and paediatrics in line with Shared Care Protocol for:

  • Dermatology
  • Gastroenterology
  • Hepatology
  • Respiratory
  • Neurology
  • Renal (Not transplant)

Rheumatology

For rheumatology please use Shared Care Protocol here.

APCO September 2019

Opthalmology

  • For opthalmology (ocular inflammation in adults and pediatrics) please see Shared Care Protocol here. 

APCO May 2019.

Red Traffic Light  For renal transplant patients as per NICE TA481 and TA482.

Funded by specialised commissioning.

APCO November 2017.

 
Link  NICE Evidence Summary: Mycophenolate for scleroderma
Link  NICE Evidence Summary: Mycophenolate for SLE
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Link  EMA advice to avoid mycophenolate use in pregnancy
Link  MHRA: Risk of hypogammaglobulinaemia & bronchiectasis with mycophenolate
   
 ....
 Non Formulary Items
Mycophenolate Sodium  (Myfortic®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended for use in renal transplant patients as per NICE TA481 and TA482. 

APCO November 2017.

Link  NICE Evidence Summary: Mycophenolate for scleroderma
Link  NICE Evidence Summary: Mycophenolate for SLE
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary